Multiplex Apolipoprotein Panel Boosts Cardiovascular Risk Prediction and Precision Therapy
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, posted on LinkedIn:
”New in ATVB (Nov 2025)
Multiplex Apolipoprotein Panel Boosts Cardiovascular Risk Prediction and Precision Therapy
In >11,800 post-ACS patients from ODYSSEY OUTCOMES, a 9-plex mass-spectrometry apolipoprotein panel outperformed the standard lipid profile in predicting:
• Major adverse cardiovascular events (MACE) (AUC 0.65 vs 0.58)
• All-cause death (AUC 0.70 vs 0.60)
The panel also identified which patients benefit most from PCSK9 inhibition (alirocumab) – paving the way for precision lipidology.
Key components: Apo(a), ApoA-I, ApoA-II, ApoA-IV, ApoB, ApoC-I, ApoC-II, ApoC-III, ApoE.
Alirocumab reduced Apo(a), ApoB, and ApoC isoforms by >30–50%.
Bottom line:
Integrated apolipoprotein profiling refines risk stratification and optimizes treatment allocation – a step forward in personalized cardiovascular medicine.
Open Access”
Title: Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy
Authors: Esther Reijnders, Patrick M. Bossuyt, J. Wouter Jukema, L. Renee Ruhaak, Fred P.H.T.M. Romijn, Michael Szarek, Stella Trompet, Deepak L. Bhatt, Vera A. Bittner, Rafael Diaz, Sergio Fazio, Irena Stevanovic, Shaun G. Goodman, Robert A. Harrington, Harvey D. White, Philippe Gabriel Steg, Gregory G. Schwartz, Christa M. Cobb
Stay informed with Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies